hereditary small vessel disease caused by mutations of the NOTCH3 gene. Clinical manifestations include migraine, recurrent ischaemic strokes, and cognitive decline. Seizures are an uncommon early symptom and usually occur after the onset of stroke. We report a CADASIL family with epilepsy as an early clinical symptom due to a novel NOTCH3 mutation. Methods The clinical histories of three family members from two generations are reported, alongside para-clinical details including results of magnetic resonance imaging (MRI), electroencephalogram (EEG), and genetic testing. Results The proband developed focal and generalised seizures at age 51. She had a preceding history of cognitive impairment and migraines. The proband's son developed focal seizures at age 25 involving his left arm and then generalised seizures. He experienced intermittent headaches, without history of stroke or cognitive impairment. His sister (the proband's daughter) had epilepsy from age 12, characterised by blank spells and generalised seizures. Cognitive decline was noted from age 38, without history of stroke. There was no family history of epilepsy in those without CADASIL. MRI in all three family members showed multifocal T2 FLAIR hyperintensities within the supratentorial white matter, particularly the temporal lobes. EEG was abnormal only in the proband's son, with paroxysmal bursts of poorly organised 3-4 Hz spike-wave activity. Genetic testing in all three family members found a novel NOTCH3 mutation, c.1337G>A p.(Cys446Tyr). Conclusion We have identified a novel NOTCH3 mutation in a kindred with epilepsy as an early manifestation of CADASIL without prior history of strokes. The association with epilepsy is unlikely to be coincidental given the strong segregation of epilepsy and CADASIL in this kindred and the clear focal seizure semiology noted in all family members. Whether this mutation represents a distinct new phenotype requires further investigation.
Case We report an unusual case of a 63 year old man who developed progressive right-sided exophthalmos, painful ophthalmoplegia, headaches and fevers with worsening depression over a two-month period, subsequently identified as an Actinomyces cavernous sinus (CS) infection. Preliminary diagnoses included giant cell arteritis then Tolosa-Hunt syndrome, with a transient response to steroids. Investigations showed a bland CSF and highly metabolically active brain FDG-PET suggesting lymphoma. Biopsy of the mass demonstrated gram-positive filamentous bacteria with Actinomyces-like colonies with sulphur granules. Actinomyces CS infections are rare. They often mimic non-infectious etiologies including other inflammatory and infiltrative conditions, vascular and neoplastic causes, particularly lymphoma. Conclusion Clinicians should consider infective CS syndromes in fluctuating painful ophthalmoplegias with poor response to steroids. In our view, "Tolosa-Hunt" should not be used as a diagnosis but merely used as a descriptor for syndromes that resolve with corticosteroids in the absence of a more precise diagnosis. Introduction The importance of prompt intervention in multiple sclerosis (MS) was described in the widely endorsed report, Brain health: time matters in multiple sclerosis.
EXPERT CONSENSUS ON STANDARDS FOR MULTIPLE SCLEROSIS CARE: RESULTS FROM A MODIFIED DELPHI PROCESS
1 The present study aimed to define standards for the timing of key steps in the care pathway. Methods An international group of 29 MS neurologists was recruited from regions with high MS prevalence to participate in a modified Delphi process. Across five rounds, they defined 'core', 'achievable' and 'aspirational' time frames (to reflect a minimum, good and high standard of MS care, respectively). A 31-member Reviewing Group of MS nurses, experts with MS and allied healthcare professionals reviewed the results and provided feedback to four Chairs. Results Consensus was reached (!75% agreement; n=21) on core, achievable and aspirational time frames for events spanning the MS care pathway. Here, we will present 21 achievable standards related to referral, diagnosis, treatment decisions, monitoring and managing new symptoms. For example, the Panel agreed that most MS teams should be aiming to 1 complete a diagnostic workup for MS within 4 weeks of a patient being referred to a neurologist, 2 assess patient eligibility for a suitable disease-modifying therapy within 3 weeks of diagnosis, 3 perform follow-up clinical evaluations every 6 months, and 4 offer an annual MRI scan. Conclusion These standards will inform tools for clinics and people with MS and act as a potential future benchmark for established and developing MS clinics across the globe aiming to deliver the highest quality care. 
